Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Exclusion Criteria

• •Prior autologous bone marrow or stem cell transplant within 6 months of study entry.
• •A history of prior allogeneic bone marrow transplant or organ transplant.
• •Previously untreated non-Hodgkin's lymphoma.
• •Previously treated with CAMPATH.
• •Patients with bulky disease, ie any single mass \> 7.5cm.
• •Prior radiotherapy to the only site of measurable disease.
• •Medical condition requiring chronic use of oral, high-dose corticosteroids.
• •Autoimmune thrombocytopenia.
• •Use of investigational agents within previous 30 days or any anti-cancer therapy within the previous 3 weeks. Patients must have recovered from all acute toxicities of any prior therapy.
• •Past history of anaphylaxis following exposure to humanized monoclonal antibodies.
• •Active, uncontrolled infection, including human immunodeficiency virus (HIV) positive.
• •Active secondary malignancy.
• •Active central nervous system (CNS) involvement with NHL.
• •Pregnant or lactating women. Male or female patients who do not agree to use effective contraceptive method(s) during the study.
• •Any significant concurrent disease or illness that would, in the opinion of the investigator, compromise patient safety or compliance, or interfere with the interpretation of study results.